Outpace Bio develops innovative cell therapies to enhance cancer treatment efficacy.
Outpace Bio has raised $144.0M in total funding. The most recent round was Series B. The last funding was announced in August 2024.
Outpace Bio's investors include Qiming Venture Partners, RA Capital Management, Playground Global, Lyell Immunopharma, Artis Ventures.
Outpace Bio is headquartered in Seattle, United States.
Outpace Bio develops innovative cell therapies to enhance cancer treatment efficacy.
Outpace Bio is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Outpace Bio — Funding & Investors." VCBacked, August 1, 2024, https://www.vcbacked.co/company/outpace-bio. Accessed September 2, 2026.
VCBacked. (2024). Outpace Bio — Funding & Investors. Retrieved September 2, 2026, from https://www.vcbacked.co/company/outpace-bio
{{cite web |title=Outpace Bio — Funding & Investors |url=https://www.vcbacked.co/company/outpace-bio |website=VCBacked |access-date=September 2, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated